CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 57 filers reported holding CRINETICS PHARMACEUTICALS IN in Q1 2020. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $12,221,385 | +97.6% | 410,941 | +19.7% | 0.00% | +100.0% |
| Q2 2023 | $6,184,086 | +309568.8% | 343,179 | +176.1% | 0.00% | +100.0% |
| Q1 2023 | $1,997 | -20.8% | 124,309 | -9.7% | 0.00% | 0.0% |
| Q4 2022 | $2,520 | -100.0% | 137,693 | -53.6% | 0.00% | -50.0% |
| Q3 2022 | $5,825,000 | -22.3% | 296,591 | -26.2% | 0.00% | -33.3% |
| Q2 2022 | $7,498,000 | +32.8% | 402,010 | +35.3% | 0.00% | +50.0% |
| Q1 2022 | $5,646,000 | -21.1% | 297,125 | +0.5% | 0.00% | 0.0% |
| Q4 2021 | $7,160,000 | +159.4% | 295,512 | +144.1% | 0.00% | +100.0% |
| Q3 2021 | $2,760,000 | -1.3% | 121,056 | -18.4% | 0.00% | 0.0% |
| Q2 2021 | $2,796,000 | +41.4% | 148,349 | +14.5% | 0.00% | 0.0% |
| Q1 2021 | $1,978,000 | +2.2% | 129,507 | -5.6% | 0.00% | 0.0% |
| Q4 2020 | $1,935,000 | -31.3% | 137,162 | -23.7% | 0.00% | 0.0% |
| Q3 2020 | $2,815,000 | +2.6% | 179,667 | +14.8% | 0.00% | 0.0% |
| Q2 2020 | $2,744,000 | +564.4% | 156,572 | +458.2% | 0.00% | – |
| Q1 2020 | $413,000 | -41.7% | 28,050 | -0.7% | 0.00% | – |
| Q4 2019 | $709,000 | +65.3% | 28,241 | -1.0% | 0.00% | – |
| Q3 2019 | $429,000 | -42.2% | 28,540 | -3.9% | 0.00% | – |
| Q2 2019 | $742,000 | – | 29,706 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Saturn V Capital Management LP | 1,126,579 | $33,504,459 | 14.02% |
| New Leaf Venture Partners, L.L.C. | 141,000 | $4,193,340 | 5.38% |
| First Light Asset Management, LLC | 1,583,329 | $47,088,204 | 4.47% |
| Paradigm Biocapital Advisors LP | 2,178,737 | $64,795,638 | 4.40% |
| Bain Capital Life Sciences Investors, LLC | 1,275,552 | $37,934,916 | 4.24% |
| Altium Capital Management LP | 262,000 | $7,791,880 | 4.06% |
| 5AM Venture Management, LLC | 462,286 | $13,748,386 | 3.96% |
| MPM BioImpact LLC | 479,053 | $14,247,036 | 3.80% |
| Affinity Asset Advisors, LLC | 450,000 | $13,383,000 | 3.76% |
| Opaleye Management Inc. | 370,000 | $11,003,800 | 3.58% |